TIDMVER

RNS Number : 7437S

Vernalis PLC

29 June 2018

TOTAL VOTING RIGHTS

VERNALIS PLC (the "Company")

29 June 2018

Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,986,000 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.

The total number of voting rights in the Company is therefore 526,986,000.

The above figure of 526,986,000 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company.

- ends -

Enquiries:

 
                                     +44 (0) 118 938 
 Vernalis plc:                                  0015 
 Ian Garland, Chief Executive 
  Officer 
  David Mackney, Chief Financial 
  Officer 
 Canaccord plc (Nominated Adviser    +44 (0) 20 7523 
  and Joint Broker):                            8000 
 Henry Fitzgerald-O'Connor 
  Emma Gabriel 
 FTI Consulting (Financial           +44 (0) 20 3727 
  Communications):                              1000 
 Ben Atwell 
  Simon Conway 
  Stephanie Cuthbert 
                                     +44 (0) 20 7653 
 Evercore (Financial Adviser):                  6000 
 Julian Oakley 
  Alan Beirne

Notes to Editors

About Vernalis

Vernalis is a revenue generating, pharmaceutical company with significant expertise in drug development. The Group has two approved products: Moxatag(R) , a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. Vernalis has also nine programmes in its NCE development pipeline in addition to significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis and Servier.

For further information about Vernalis, please visit www.vernalis.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRUBUKRWWANURR

(END) Dow Jones Newswires

June 29, 2018 02:00 ET (06:00 GMT)

Vernalis (LSE:VER)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Vernalis.
Vernalis (LSE:VER)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Vernalis.